ARS Pharmaceuticals, Inc. (SPRY) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A indicate strong growth in Neffy's sales and positive market reception, demonstrated by a 64% increase in revenue and increased prescriptions. The DTC campaign is expected to further drive growth. However, there is some concern about the ceiling for commercial coverage without prior authorization. Despite this, the overall sentiment is positive due to strong financial performance and optimistic future guidance.
Key Financial Performance
Net Product Revenue for Neffy $12.8 million in Q2 2025, reflecting a 64% increase compared to Q1 2025. This growth was driven by the availability of the 1-milligram pediatric dose starting in May and steady traction with payers.
Total Revenue $15.7 million in Q2 2025. This includes $12.8 million from U.S. net product revenue and $2.9 million from collaboration and supply revenue. The collaboration revenue includes a $5 million milestone payment from ALK related to the launch of EURneffy in Germany.
R&D Expenses $4 million in Q2 2025, primarily related to the initiation of the Phase IIb urticaria trial and continued clinical and development expenses for Neffy.
SG&A Expenses $54.3 million in Q2 2025, reflecting investments in the National DTC campaign and continued sales and marketing efforts for Neffy.
Gross to Net Retention Moved to the low 50% range in Q2 2025 from mid-60% in Q1 2025. This reflects the success of the payer access strategy, with an increasing volume of Neffy prescriptions now covered without prior authorization.
Cash Position $240.1 million in cash, cash equivalents, and short-term investments as of the end of Q2 2025, providing over 3 years of operating runway.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Neffy commercial momentum: Neffy achieved $12.8 million in net product revenue in Q2 2025, driven by the availability of the 1-milligram pediatric dose and increased payer traction. Prescriptions grew by 180% in weekly two-pack unit volume from Q1 to Q2 2025.
Global expansion of Neffy: Neffy was launched in Germany in June 2025 and approved in the UK in July 2025. Regulatory decisions in Canada, Australia, Japan, and China are expected by 2025-2026.
New clinical trial for Neffy: Initiated a Phase IIb clinical trial for chronic spontaneous urticaria, with top-line data expected in the first half of 2026.
U.S. market expansion: Neffy achieved 93% commercial insurance coverage, with 57% of payers not requiring prior authorization. The 'Hello Neffy, Goodbye Needles' DTC campaign increased awareness, with nearly 50% of surveyed respondents recalling the advertisement.
School adoption: Over 3,200 schools joined the Neffy in Schools program, and 14 states updated legislation to allow school employees to administer Neffy.
Sales organization reach: The 118-person sales team engaged 15,000 healthcare providers, with 9,700 having dispensed Neffy prescriptions.
Payer engagement: 93% commercial coverage achieved, with streamlined prior authorization processes and co-pay assistance reducing patient costs to $25.
Global regulatory strategy: Focused on approvals in key international markets (Canada, Australia, Japan, China) and expanding Neffy’s pediatric dose in Europe by 2026.
Pipeline expansion: Advancing the urticaria program for potential label expansion.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approvals: The company is awaiting regulatory decisions for neffy in Canada, Australia, Japan, and China, as well as approval for the 1-milligram pediatric dose in the EU. Delays or unfavorable decisions could impact global expansion and revenue growth.
Supply Chain and Inventory: A one-time inventory reserve for older inventory was established, indicating potential challenges in inventory management. This could lead to increased costs or supply disruptions if not addressed.
Payer Coverage and Prior Authorization: While 93% commercial coverage has been achieved, 57% of commercial payers still require prior authorizations (PAs). Although PA approval rates are high, the process could deter healthcare providers and patients, impacting prescription growth.
Marketing and Consumer Awareness: The success of the direct-to-consumer (DTC) campaign is critical for driving demand. Delays in consumer action or insufficient campaign impact could hinder prescription growth and market penetration.
Financial Sustainability: The company is heavily investing in marketing and sales, with SG&A expenses reaching $54.3 million in Q2. While the cash position is strong, sustained high expenses could strain financial resources if revenue growth does not meet expectations.
Global Expansion Risks: The company is relying on international partners for global expansion. Any underperformance or delays by these partners could impact the rollout and adoption of neffy in key markets.
Clinical Trials and Pipeline Development: The Phase IIb clinical trial for chronic spontaneous urticaria is underway. Delays or unfavorable outcomes could impact the company's ability to expand its product pipeline and achieve label expansion.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Future growth in neffy prescriptions: The company expects greater growth in neffy prescriptions in the third and fourth quarters of 2025, driven by the rollout of a national DTC campaign, U.S. pediatric co-promotion with ALK, and the peak prescribing season of late summer and early fall.
Global expansion of neffy: Regulatory decisions on neffy are expected in Canada, Australia, and Japan by the end of 2025, and in China by the first half of 2026. Commercial rollout in these regions is anticipated to start in the first half of 2026. Approval of the 1-milligram pediatric dose by the European Medical Agency is expected in the first half of 2026, triggering a $5 million milestone payment from ALK.
Clinical trial for urticaria: A randomized controlled Phase IIb clinical trial for chronic spontaneous urticaria is underway, with top-line data anticipated in the first half of 2026.
Gross to net retention guidance: The company expects to maintain a gross to net retention level of approximately 50%, providing greater predictability in future revenue modeling.
Financial position and investments: The company has over three years of operating runway with $240.1 million in cash, cash equivalents, and short-term investments as of Q2 2025. Substantial investments in the launch of neffy, including a $50 million DTC campaign, are expected to drive both short- and long-term market share capture.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you confirm the number of prescriptions written or shipped during the quarter?
A:There were approximately 35,000 prescriptions (2 packs) in the quarter, compared to 19,000 in the first quarter. This was calculated based on $12.8 million in net sales and a gross-to-net ratio of roughly 52%.
Q:Are there any early signs that the DTC campaign is translating into actual prescribing behavior?
A:The linear TV campaign started in early July, and it typically takes 12 to 16 weeks to see significant impact. There is feedback indicating that people are noticing the ads and acting on them, but it may take time for this to translate into significant uptick due to appointment scheduling delays.
Q:Are you seeing patients who previously lapsed prescriptions coming back to fill prescriptions for neffy?
A:Yes, there is a mix of patients switching to neffy, reengaged patients due to its needle-free and easy-to-carry features, and lapsed patients who opted out previously due to the needle. A more extensive claims analysis is planned for the fourth quarter to better understand these trends.
Q:What is the realistic ceiling for commercial coverage without prior authorization, and can you quantify the revenue impact of moving the remaining Zinc portion to full coverage?
A:About 25% of CVS companies under Caremark cover neffy without prior authorization, while the rest require it. There are no companies within the Zinc network blocking neffy. The prior authorizations are steady but concentrated among companies not yet offering open access. No signs of a ceiling have been observed.
Q:Which factors are driving the strong growth in weekly scripts, and how long will the DTC campaign last?
A:The DTC campaign and expanded sales force through the ALK partnership are major drivers. The campaign is budgeted to continue through 2026, with adjustments based on effectiveness data. Seasonal factors also contribute to growth.
Q:What is the impact of the back-to-school season on scripts, and are patients getting multiple packs?
A:The back-to-school season has led to increased orders for multiple packs of neffy. Parents often want their children to have one at all times, and programs like neffyconnect encourage multiple pack purchases. The company has also updated its co-pay policy to charge $25 for multiple cartons, which has driven higher orders.
Q:What is the timeline for feeling the full impact of the DTC campaign, expanded reach from ALK promotion, and availability of the 1 mg neffy?
A:The typical timeline for DTC impact is 12 to 16 weeks, but the August-September peak may accelerate this due to pre-scheduled appointments. These factors are expected to sustain quarter-over-quarter growth in Q4 despite seasonality.
Q:What are the biggest indicators that neffy is starting to take meaningful bites out of the larger market that doesn't regularly carry or use epinephrine?
A:Anecdotal evidence suggests that some patients who never used auto-injectors are now purchasing neffy. A thorough market analysis is planned later this year to better understand the market segments contributing to growth.
Q:Review of Unclear Management Responses
A:Management appeared to avoid directly answering the question about the realistic ceiling for commercial coverage without prior authorization. While they provided some context about current coverage and trends, they did not clearly address whether 93% coverage is the peak or if there is room for further growth.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CVS Caremark
Chakma Chief
EURneffy Germany
Inc Research
National
PAs patient
PBMs
Phase IIb
Research Division
ad
balance sheet
care professional
cash position
change
emergency
environment
epinephrine market
financing liability
increase
initiation Phase
intranasal epinephrine
inventory
liability balance
milestone payment
modeling
payer access
phase
prescribing experience
retention
rollout
traction
SPRY Transcript
ARS Pharmaceuticals, Inc. (SPRY) Q1 2026 Earnings Call Transcript
Positive5-15
The earnings call reflects a positive outlook with strategic expansions, improved payer access, and a strong international presence. Despite some lack of clarity in management's responses, there is confidence in achieving breakeven by mid-2027 and significant market share growth. The absence of a market cap suggests a potential strong reaction, but overall, the strategic initiatives and positive guidance point to a likely positive stock price movement in the short term.
ARS Pharmaceuticals, Inc. (SPRY) Q4 2025 Earnings Call Transcript
Unknown3-9
The earnings call presents a mixed outlook. Financial performance is stable with positive revenue growth and a solid cash balance. However, challenges exist in regulatory and coverage hurdles, and SG&A expenses are high. The Q&A reveals some concerns about inventory dynamics and the unclear timeline for unrestricted access. Despite strategic initiatives and global expansion plans, the overall sentiment remains neutral due to the lack of immediate catalysts and ongoing uncertainties in coverage and market expansion.
ARS Pharmaceuticals, Inc. (SPRY) Q3 2025 Earnings Call Transcript
Positive11-10
The company reported strong growth in neffy prescriptions and revenue, with a 2.5-fold increase in U.S. net product revenue. Despite a net loss, the financial health remains stable with significant cash reserves. The Q&A highlighted positive feedback from new initiatives and optimism about future growth through partnerships and expanded market access. While some uncertainties exist, such as reliance on a term loan and inconsistent institutional sales, the overall sentiment is positive due to revenue growth, strategic initiatives, and optimistic guidance.
ARS Pharmaceuticals, Inc. (SPRY) Q2 2025 Earnings Call Transcript
Positive8-13
The earnings call summary and Q&A indicate strong growth in Neffy's sales and positive market reception, demonstrated by a 64% increase in revenue and increased prescriptions. The DTC campaign is expected to further drive growth. However, there is some concern about the ceiling for commercial coverage without prior authorization. Despite this, the overall sentiment is positive due to strong financial performance and optimistic future guidance.
SPRY Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
